801 related articles for article (PubMed ID: 11309439)
1. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
2. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
[TBL] [Abstract][Full Text] [Related]
3. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
4. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
[TBL] [Abstract][Full Text] [Related]
6. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
[TBL] [Abstract][Full Text] [Related]
7. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
11. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
12. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
13. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
Fehr MK; Hornung R; Varga Z; Burger D; Hess T; Haller U; Fink D; von Schulthess GK; Steinert HC
Breast J; 2004; 10(2):89-93. PubMed ID: 15009033
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Kuwano H
Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
16. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
18. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
19. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
Futamura M; Asano T; Kobayashi K; Morimitsu K; Nawa M; Kanematsu M; Morikawa A; Mori R; Yoshida K
World J Surg Oncol; 2015 Feb; 13():49. PubMed ID: 25885028
[TBL] [Abstract][Full Text] [Related]
20. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer.
Lovrics PJ; Chen V; Coates G; Cornacchi SD; Goldsmith CH; Law C; Levine MN; Sanders K; Tandan VR
Ann Surg Oncol; 2004 Sep; 11(9):846-53. PubMed ID: 15313737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]